STAT3 and melanoma: Taken together, the results of our study showed that local administration of low-dose CpG-Stat3 siRNA can enhance the therapeutic potential of IBC in B cell lymphoma and melanoma mouse tumor models, supporting further testing and development of CpG-Stat3 siRNA and ICB combinatory treatment for clinical application.